Tag: Cell Therapy
-
Can New Data Rescue Capricor’s Duchenne Cell Therapy at the FDA?
Capricor is submitting new 24-month upper-limb data for deramiocel after an FDA advisory committee voted against the existing efficacy evidence, reopening the regulatory debate around the DMD cell therapy.
-
J&J Takes a Profit Hit to Secure an In Vivo CAR-T Platform
Johnson & Johnson accepted near-term earnings pressure to secure access to Sail Biomedicines’ in vivo CAR-T platform, placing a major bet on scalable cell-therapy delivery.